Skip to Main Content

Paper Details

Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma.
Neuro-Oncology Advances
4
2022
EVs, GBM, GBM stem cells, GSCs, Hypermutant tumors, PD-1, PD-L1, TMZ, extracellular vesicles, glioblastoma, hypermutant tumors, immune cell, patient, patients, recurrent glioblastoma, temozolomide, tumors

Datasets

Release 1.2